State Street Corp. Maintains Significant Stake in Agios Pharma
Ticker: AGIO · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**State Street still holds Agios Pharma stock, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Agios Pharmaceuticals Inc. common stock as of December 31, 2023. This filing is an update to their previous disclosures, confirming their continued significant, but passive, stake in the pharmaceutical company. This matters to investors because State Street's continued holding suggests a long-term, institutional confidence in Agios Pharmaceuticals, which could be a positive signal for the stock's stability.
Why It Matters
This filing confirms a major institutional investor's continued interest in Agios Pharmaceuticals, which can influence market perception and investor confidence.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate change in company operations or significant market risk.
Analyst Insight
Investors should note that State Street Corporation, a large institutional investor, continues to hold a position in Agios Pharmaceuticals. While this doesn't signal an immediate buy or sell, it suggests a stable institutional presence. Smart investors might look for further details on the exact percentage of ownership in the full filing to gauge the significance of this continued stake.
Key Players & Entities
- State Street Corporation (company) — the reporting person filing the SC 13G/A
- Agios Pharmaceuticals Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
- 00847X104 (other) — the CUSIP number for Agios Pharmaceuticals Inc. common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' section and the 'SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING' title.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as clearly identified under '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION'.
What is the subject company whose securities are being reported?
The subject company is AGIOS PHARMACEUTICALS, INC., as indicated by 'NAME OF ISSUER: AGIOS PHARMACEUTICALS INC' and 'COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC.'.
What is the date of the event that required this filing?
The date of the event which requires the filing of this statement is December 31, 2023, as specified under 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: 12/31/2023'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B)' section.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding AGIOS PHARMACEUTICALS, INC. (AGIO).